Recruiting

ECALMIST vs. InSurE

Sponsor:

University of Manitoba

Code:

NCT01848262

Conditions

Respiratory Distress Syndrome

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

ECALMIST

InSure

Study Details

Brief summary:

Minimally invasive surfactant therapy via a small vascular catheter - ECALMIST (Early CPAP And Large Volume Minimal Invasive Surfactant Therapy) versus InSurE (Intubate, Surfactant Extubate) in preterm infants with Respiratory Distress Syndrome (RDS): A prospective randomized clinical trial.

Conditions

Respiratory Distress Syndrome

Study ID

NCT01848262

Start date

Jun, 2013

Status verified date

Feb, 2014

Completion date

Jun, 2015

Anticipated

Primary completion date

Jun, 2015

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

All should apply:

  • Newborn less than 32 weeks gestation at birth
  • Postnatal age < 24 hrs of life
  • Clinical diagnosis of RDS
  • Spontaneously breathing on NCPAP
  • Clinical decision to give surfactant.

Exclusion Criteria:

  • Lack of parental consent.
  • Need for mechanical ventilation
  • Major congenital malformation

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: ECALMIST

ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant

experimental: InSurE

InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant

Interventions

ECALMIST

Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.

InSure

Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.

Primary outcome measure

  • Incidence of early ventilation hours [ Time Frame: 3 days ]

Central Contacts and Locations

Central contacts

Locations

Health sciences Center

Recruiting

Winnipeg, Manitoba, Canada

Contacts

Principal Investigator:

Yahya Ethawi, MD

More Information

Sponsor

University of Manitoba

Last update posted

Feb 11, 2014

Last verified

Feb, 2014

Keywords

  • ECALMIST
  • InSurE
  • CPAP
  • Ventilation
  • Vascular Catheter

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Manitoba on 2014-02-11.